PDCD1 and Hepatic fibrosis: Even if not statistically significant, we observed more cholangitis (67% vs. 36%, p = 0.509) and liver fibrosis (50% vs. 21%, p = 0.070) in patients receiving combination treatment as compared to anti PD-1 monotherapy.